Leading the way on research on leishmaniasis in the UK
At the University of York, our research on leishmaniasis encompasses the full life cycle of the parasite and spans molecular parasitology, immunology, animal models and clinical trials.
YorkLeish showcases the research being carried out in York, and provides a central point to access details of those undertaking research, current projects and publications.
A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
Researchers at the University of York have identified genes in a parasite that could help clinicians predict drug treatment outcomes for patients with visceral leishmaniasis in Brazil.
PREV_PKDL (P Kaye, C Lacey) is a collaborative project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme supported by the European Union.
The PREV_PKDL project aims at advancing the clinical development of ChAd63-KH vaccine for the prevention of post kala azar dermal leishmaniasis (PKDL). We will evaluate ChAd63-KH in two clinical trials in clinically cured visceral leishmaniasis (VL) patients. The results of these trials will be decisive in the future development of ChAd63-KH.
A major aim of this project is to support the Leishmaniasis East Africa Platform (LEAP) in its ambitions, by extending its research capacity in immunology and vaccine development. This capacity strengthening will help LEAP to develop as a major force for research and training on poverty-related neglected diseases in the East African Region.